Back to Search

JAE KIM, M.D.

M.D.

Specialist

NPI: 1083685218IndividualAccepts Medicare

Specialties, Licenses & Credentials

SpecialistPrimary

Specialist

Code: 174400000X

L9286(TX)

CMS Specialties

PrimaryGASTROENTEROLOGY

Additional

INTERNAL MEDICINE

Education

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE

Class of 1998

Clinical Trials (1)

1
Linked Trials
0
Recruiting
0
With Results

Risankizumab Long-term Remission Study

NCT04630652ACTIVE_NOT_RECRUITINGPHASE4PRINCIPAL_INVESTIGATOR

Research & Publications (20)

Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
6421 SARATOGA BLVD., BLDG. 106
CORPUS CHRISTI, TX 78414

Quick Facts

NPI
1083685218
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
28
Clinical Trials
1
Publications
20

Are you this provider?

Claim Your Profile